

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**January 22, 2018**

Date of Report (Date of earliest event reported)

**AEVI GENOMIC MEDICINE, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**1-35112**  
(Commission File Number)

**98-0217544**  
(I.R.S. Employer  
Identification No.)

**435 Devon Park Drive, Suite 715  
Wayne, Pennsylvania 19087**  
(Address of principal executive offices, zip code)

**(610) 254-4201**  
(Registrant's telephone number, including area code)

Not Applicable  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(e) On January 22, 2018, the Compensation Committee of the Board of Directors of Aevi Genomic Medicine, Inc. (the “Company”) approved a cash retention bonus plan for certain employees of the Company (the “Retention Plan”). The Retention Plan included the award of a cash retention bonus to Brian D. Piper, the Chief Financial Officer of the Company, in the amount of \$330,000. Mr. Piper’s cash retention bonus will vest on December 1, 2018 if Mr. Piper remains continuously employed by the Company through such date.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 6, 2018

AEVI GENOMIC MEDICINE, INC.

By: /s/ Michael F. Cola  
Michael F. Cola  
President and Chief Executive Officer  
(principal executive officer)

---